All right. So we're going to get started. Good morning, everybody. Thank you so much for joining the Regeneron session at the Leerink Global Healthcare Conference. It's my pleasure to welcome ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...

NFL Network star Colleen Wolfe knows that women athletes deserve to have significant moments highlighting their impact. Wolfe, who has been with NFL Network since 2014, spends her days talking ...

Using CytomX’s Probody and Regeneron’s Veloci-Bi platforms, the collaboration and licensing agreement aims to enable the development of investigational next-generation bispecific immunotherapies.

--Currently up four consecutive days; up 10.44% over this period --Longest winning streak since Feb. 25, 2025, when it rose for six straight trading days --Best four day stretch since the four ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA ...

Colleen Kane is the college sports reporter for the Chicago Tribune. She has worked at the Tribune since 2007, starting in high school sports before moving to the White Sox and then the Bears.